Infantile-onset thiamine responsive megaloblastic anemia syndrome with SLC19A2 mutation: a case report.

Related Articles

Infantile-onset thiamine responsive megaloblastic anemia syndrome with SLC19A2 mutation: a case report.

Arch Argent Pediatr. 2017 Jun 01;115(3):e153-e156

Authors: Katipoğlu N, Kampımar TH, Demir K, Aydin Köker S, Nalbantoğlu Ö, Ay Y, Korkmaz HA, Oymak Y, Yıldız M, Tunç S, Hazand F, Vergin C, Ozkan B

Abstract
BACKGROUND: Thiamine-responsive megaloblastic anemia syndrome (TRMA), also known as Rogers syndrome, is characterized by megaloblastic anemia, sensorineural hearing loss, and diabetes mellitus. Disturbances of the thiamine transport into the cells results from homozygous or compound heterozygous mutations in the SLC19A2 gene.
CASE PRESENTATION: We report a girl which presented with sensorineural deafness treated with a hearing prosthesis, insulin requiring diabetes, macrocytic anemia, treated with thiamine (100 mg/day). Hemoglobin level improved to 12.1 g/dl after dose of thiamine therapy increased up to 200 mg/day.
CONCLUSION: Patients with TRMA must be evaluated for megaloblastic anemia, sensorineural hearing loss, and diabetes mellitus. They must be followed for response of hematologic and diabetic after thiamine therapy. It should be kept in mind that dose of thiamine therapy may be increased according to the clinical response. Genetic counseling should be given.

PMID: 28504500 [PubMed - in process]

from ORL via xlomafota.13 on Inoreader http://ift.tt/2pSnsju
via IFTTT

http://ift.tt/2rbOIOR